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Background: We have sought to identify ethnic- and gender-specific differences in HIV prevalence among heroin
users receiving opioid maintenance treatment in the canton of Zurich, Switzerland.
Methods: We used a generalized linear model (GEE) to analyze data from the anonymized case register for all
opioid maintenance treatments in the canton of Zurich. Patients who received either methadone or buprenorphine
between 1991 and 2012 (n = 11,422) were evaluated for gender (male vs. female), ethnic background (Swiss vs.
non-Swiss), and lifetime method of drug use (ever injector vs. non-injector). We addressed missing data by multiple
imputation.
Results: The overall prevalence of HIV among patients declined substantially from 33.7% in 1991 to 10.6% in 2012
in the complete dataset. In the imputed datasets, the respective prevalence dropped from 32.8% in 1991 to 9.7% in
2012. Non-injectors had a four to five times lower risk ratio (RR) compared to the reference group, ‘Swiss males who
ever injected’. In addition, we found a significantly higher risk ratio of HIV prevalence among females who had ever
injected; this was true both for the complete dataset and the imputed dataset (Swiss RR 1.18 CI 95% 1.04–1.34,
non-Swiss RR 1.58 CI 95% 1.18–2.12).
Conclusion: In this population, gender, ethnic background, and lifetime method of drug use influenced the risk of
being HIV positive. Different access to treatment and different characteristics of risk exposure among certain
subgroups might explain these findings. In particular, the higher risk for women who inject drugs—especially for
those with an immigrant background—warrants additional research. Further exploration should identify what
factors deter women from using available HIV-prevention measures and whether and how these measures can be
better adapted to high-risk groups.Background
Methadone as HIV prevention
Opioid maintenance treatment (OMT) with methadone
or buprenorphine is widely recognized as an effective
HIV-prevention intervention for patients with an opioid
dependence [1-5]. It has proved beneficial for injection
drug users (IDU) and non-injection drug users (non-
IDU) alike and is associated with a reduction in the in-
cidence of HIV [6]. Patients in OMT use significantly
less street opiates and in the case of IDUs, reduce the* Correspondence: Michael.Liebrenz@uzh.ch
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unless otherwise stated.frequency of opiate injection and needle sharing [7-9].
The association between injection drug use and increased
risk for acquiring HIV has been well documented for over
20 years [10], and it is clearly understood today that OMT
reduces injection-related HIV risk behaviors [1,10,11].
However, OMTs’ usefulness is not limited to IDUs [1]:
Multiple studies have shown that besides sexual contact
with an IDU, alcohol and non-injection drug use represent
significant risk factors for the acquisition of a new HIV in-
fection in both genders, regardless of sexual orientation
[6,12-14]. Among opioid-dependent patients trading sex
for drugs, low-threshold access to OMT is known to sig-
nificantly reduce engagement in prostitution and with it
to decrease total numbers of sex partners and rates of un-
protected sex [15,16]. Because of its vast health benefits,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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prevention strategy; accordingly, methadone was included
in the WHO list of essential drugs in 2005 [17,18].
Prevalence of HIV among injection drug users
Data from the Swiss Federal Office of Public Health
(SFOPH) indicate that the introduction of harm-reduction
policies such as needle and syringe programs (NSP), as
well as supervised consumption rooms (SCR) and the
availability of OMT, resulted in a sharp decrease in the in-
cidence of new HIV infection among IDUs: from more
than 900 new infections in 1989 to 28 new positive tests
in 2008 [19-22].
The prevalence of HIV in this subgroup has been re-
ported to be fairly stable: between 5% for IDUs in a
treatment setting and 10% in low-threshold facilities
(LTF), such as needle and syringe programs or drug con-
sumption facilities [23]. These data resulted from cross-
sectional surveys conducted in 1993, 1994, 1996, 2000,
and 2006 by means of questionnaires distributed to IDUs
in LTFs in ten different cantons in Switzerland [24]. It is
thereby estimated that over half of IDUs frequenting LTFs
simultaneously receive OMT [23].
Additional data on the prevalence of IDU among HIV-
infected patients stem from the Swiss HIV Cohort Study
(SHCS), which originated in 1988 [25]. Since then, the
study has continuously followed patients with HIV who
undergo treatment at any of the five university hospitals
in Switzerland, or in SHCS-associated regional hospi-
tals or private doctors’ offices [26]. By March 2009, the
SHCS covered a total of 15,624 patients, which is esti-
mated to represent 45% of the cumulative number of
HIV infections known to SFOPH and 69% of individuals
with AIDS who reside in Switzerland. It was estimated
that 29.5% of all ever-registered patients were infected
through injection drug use and that 16.8% of those cur-
rently in treatment were similarly infected (data as of
2009) [26].
Ethnicity, gender, substance use disorder, and HIV
Multiple studies have shown that immigration is often
associated with increased substance use because of social
difficulties and stressors [27] and that while patterns of
substance use begin to resemble that of the native popu-
lation over time [28], immigrants are initially more likely
to engage in riskier injection behaviors and to share sy-
ringes [29,30]. Women with an immigration background
and co-occurring substance use disorders are estimated
to have an elevated risk of contracting HIV, either by
injecting drugs, having sex with an injecting drug user,
or through other high-risk sexual behaviors and absence
of condom use [31,32]. Extensive literature shows that il-
legal immigrant women might be at increased risk of
HIV either because of engaging in sex work or survivalsex (e.g., exchanging sex for shelter, money, or other re-
sources). This is due to the lack of employment [33-36].
Furthermore, studies from North America among
White, African American, and Hispanic women participat-
ing in methadone maintenance suggest ethnic differences
in substance use and sexual behaviors that increase the
relative risk of HIV infection [31,37-39]. According to
Grella et al. [39], Hispanic women more frequently stated
familial influences, irregular condom use, and high-risk in-
jection behavior. White women reported the highest levels
of consistent condom use but were the least likely to use
safer injection practices; and African-American women
reported more use of alcohol and crack cocaine, both be-
fore and after entering OMT [39].
To our knowledge, however, epidemiological data on
rates of correlation between HIV infection and gender
and ethnicity in opioid maintenance treatment are not
readily available, despite these cited findings.
Immigrants in Switzerland and Zurich
Switzerland has one of the largest foreign populations but
is not regarded by most natives as an immigration country
[40]. In recent years, the population of Switzerland grew
by approximately 80,000 immigrants per year, mostly due
to the needs of Switzerland’s economy [41,42]. In January
2013, the canton of Zurich had 1,406,000 inhabitants. As
of November 2013, the canton of Zurich had 356,753 per-
manent non-Swiss residents. Of these residents, 190,262
were men and 166,491 were women, 239,364 were citizens
of an EU-28 or EFTA country, 9,676 were from Africa,
15,895 were from America (North, Central, and South),
and 23,284 were from Asia [43]. Thus, the proportion of
immigrants to Swiss nationals in the canton of Zurich was
25.4%. The number of illegal immigrants is relatively
small. In 2005, it was estimated that about 20,000 inhabi-
tants of the canton of Zurich had no legal documentation
[44]. Our case, register includes all patients receiving
OMT, regardless of their immigration status. It is manda-
tory for legal residents to carry health insurance (that
covers OMT); if they do not have sufficient personal funds
to buy it, the social welfare office steps in and covers the
fees [45-47]. Illegal immigrants have access to the health
care system, which requires all physicians to help those in
need. Furthermore, public hospitals are required by law to
provide treatment and not just emergency aid. Thus, ac-
cess to the medical system for individuals without legal
documentation is largely secured [48].
Open questions
While data have shown that the introduction of harm-
reduction policies in Switzerland significantly decreased
the incidence of HIV and a stable prevalence of this
virus in the general substance-using population, less is
known about ethnic- and gender-specific differences in
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oid maintenance treatment. The aim of our investiga-
tion was therefore to explore these issues by evaluating
a comprehensive case register of maintenance treat-
ments in the canton of Zurich. For the purpose of this
investigation, we defined ‘immigrants’ as migrants to
Europe—and more specifically to Switzerland.
Methods
Study area
Switzerland is a federal republic consisting of 26 can-
tons. It covers 15,940 square miles and has approxi-
mately 7.8 million inhabitants. Its most populous canton
is Zurich, with 1.35 million residents, of whom 23.8%
(321,000) are legal aliens [49].
In the mid-1990s, prevalence rates for opioid depen-
dence were estimated at about 0.9% [50]. Since then, the
Swiss Federal Office of Public Health and numerous
other studies have reported a decrease in the prevalence
of heroin use, which is estimated today to affect 18,500
to 25,000 individuals in Switzerland [19,23]. Still, ap-
proximately 25% of all heroin users live and die in the
canton of Zurich [51].
Database
Switzerland’s controlled substances legislation requires
every initiation and termination of an opioid mainten-
ance treatment to be registered with cantonal health au-
thorities. Each of its 26 cantons is thereby obliged by
law to maintain an independent database on treatment
numbers [52,53]. Our research group has been accre-
dited by the health authorities of the canton of Zurich to
operate and evaluate its case register of maintenance
treatments with methadone or buprenorphine. However,
this mandate does not include the collection of data on
heroin-assisted treatments.
Upon initiation of OMT, physicians are required to
provide detailed but anonymous information about pa-
tients by completing a standard admission from. The
questionnaire, which is also distributed at least twice
annually (follow-up form) and at the end of treatment
(discharge form), contains 24 questions on personal in-
formation (age, sex, nationality), previous substance use
(drug of choice, frequency of consumption, type of appli-
cation), and psychosocial characteristics (living conditions,
educational level, employment status, interpersonal rela-
tionships), as well as former maintenance treatments and
patients’ progress in current treatment (results of urinaly-
ses, number of take-home doses). Special attention has
been paid to document changes in the serological status of
HIV, HBV, HCV, and vaccination status (HBV). On the
admission form, physicians are asked to document whe-
ther a patient had been tested for HIV and to report the
current status. However, answer choices include an optionto keep this information confidential. These data are not
solely collected for evaluation purposes—they are also
used to call physicians’ attention to the possibility of infec-
tious diseases in this high-risk group.
An individual code is assigned to each registration.
This allows unequivocal identification of patients, fol-
lowing, for example, a change of treatment providers or
an interruption of OMT. To ensure completeness of in-
formation, several measures are applied: The database
software checks the appropriate range of data inputs and
generates letters for providers who have failed to meet
the requirements. Furthermore, prescriptions for metha-
done and buprenorphine issued by physicians in Zurich
are controlled.
Statistical analysis
The case register was established in 1991. From then
until April 2013, we had registered 32,667 treatment epi-
sodes with 11,468 patients, which we defined as unin-
terrupted opioid maintenance treatments by the same
provider using the same kind of opioid. Using data from
admission forms, we obtained information about gender
from almost all patients (except for 5.9%), if they were
Swiss citizens or not (except for 12.8%) and if they had
ever injected drugs (except for 7.7%). By using additional
data from follow-up forms (which were distributed
6 months after admission for treatment) and data from
discharge forms, we obtained HIV status on three out of
four patients (except for 26.4%). As most patients had
had several treatment episodes, we observed those whose
lifetime injecting status changed over time (n = 1,369), as
well as the few patients who had become HIV positive
(n = 317). If available, we always applied the estimated
year of status change to our analysis. Because we were
missing data in regard to different variables, a complete
dataset analysis could only utilize the information gath-
ered from 65.9% of the total sample. We therefore applied
the multiple imputation procedure implemented in the
statistical software, SPSS 18.0.3, by using all variables of
our model of interest (MOI) with fully conditional specifi-
cation (FCS), including two-way interactions for nominal
variables; and we set the number of imputed datasets to
ten. We checked imputation for plausible values and made
small corrections in fewer than eight cases of each im-
puted dataset, in order to maintain consistency.
For analysis, we produced a long dataset structure with
one record per patient for each year, if he or she was in
substitution treatment. For example, a patient whose
first treatment episode began in 1992 and ended in 1994
and then had a second treatment episode of 2 months in
2000 was represented with four records in the long data-
set (i.e., with the calendar year set to 1992, 1993, 1994,
and 2000). Each record consisted of the following vari-
ables: a subject identifier, number of record of the subject,
Liebrenz et al. Harm Reduction Journal 2014, 11:23 Page 4 of 9
http://www.harmreductionjournal.com/content/11/1/23calendar year, year of birth, current age (=calendar year −
year of birth), gender, nationality (Swiss or non-Swiss),
current lifetime injecting status, and current HIV status.
As the overall proportion of HIV-positive patients in
substitution treatment was greater than 10%, we mod-
eled risk ratio (RR) instead of an odds ratio (OR), since
the differential between the RR and OR increases with
increasing rates. Therefore, we applied the extension of
the modified Poisson regression model to prospective
studies, with correlated binary data proposed recently by
Zou and Donner [54]. The modified Poisson model was
estimated by generalized estimating equation (GEE)
method, using Poisson distribution and log as link func-
tion, and a repeated subject identifier for each patient,
with an independent working correlation structure and
robust estimator for covariance matrix, developed by
Liang and Zeger [55]. The modified Poisson model does
not have the convergence problems that commonly
arise with log-binomial regression and is therefore a vi-
able approach for estimation of risk ratio as an aggregated
effect measure but is not a suitable procedure for predict-
ing individual risk [54].
In order to find and present a parsimonious model, we
rescaled year of birth and age with linear, squared, and
cubic components that well fitted the observed data.
Also, calendar year was rescaled and the logarithm taken.
Note that the chosen rescaling and transformations
do not have a clear interpretation itself as minor mo-
difications of the used parameters would lead to simi-
lar GEE fits. As the parameter estimates of the GEE
model are hard to interpret, we show figures giving
the observed and model-fitted HIV prevalence in the
complete and imputed dataset plotted by calendar year,
year of birth, or age.
Ethics
Zurich’s cantonal ethics committee approved the analysis
of data.Table 1 Sample description using the long dataset (one recor






Female, non-Swiss, non-injector 185 215.3
Female, non-Swiss, ever injector 188 225.5
Female, Swiss, non-injector 1,105 1,298.4
Female, Swiss, ever injector 1,505 1,738.2
Male, non-Swiss, non-injector 941 1,124.5
Male, non-Swiss, ever injector 830 984.9
Male, Swiss, non-injector 2,245 2,643.0
Male, Swiss, ever injector 2,733 3,192.2Results
Between 1991 and 1995, the annual number of patients
in OMT with methadone or buprenorphine in the can-
ton of Zurich increased from 2,015 to 3,736, remained
almost stable until 2010, and then slightly declined in
2012 to 3,215 patients. During this period, we registered
11,422 patients, all of whom were included in the ana-
lysis using the imputation dataset, whereas the complete
dataset analysis could use only the data from 7,557 pa-
tients due to missing data in relation to gender, national-
ity, and injecting or HIV status.
According to the first subject record in the long data-
set, the group size of non-Swiss females who had never
injected was n = 185 in the complete dataset as well as
in the ten imputed datasets with mean size of 215.3 indi-
viduals, the smallest group (Table 1). Non-Swiss females
who never had injected had also the lowest mean num-
ber of about five records in the long dataset as well as
the lowest mean age of about 32 years compared to the
other groups. The most sizable group was Swiss males
who had ever injected (N = 2,733) in the complete data-
set, as well as in the imputed datasets (mean of n =
3,192.2). This group had the highest mean age in the
long dataset (36 years). Overall, apart from size, the
groups did not strongly deviate with respect to age and
number of records, in both the complete and the im-
puted datasets.
Prevalence of HIV among all patients in OMT in the
canton of Zurich has declined substantially over the
course of the last 20 years. In 1991, the prevalence was
33.7%, whereas in 2012, it was only 10.6% in the complete
dataset; in the imputed datasets, the respective prevalence
dropped from 32.8% in 1991 to 9.7% in 2012. Our GEE
model showed a quite complicated influence structure of
age and year of birth, requiring linear, squared, and cubic
components of both variables to fit the observed HIV
prevalence. As these effects are hard to interpret from the
numerical output (Table 2), we produced graphs showingd per patient for each year being in treatment)










5.07 4.95 31.9 32.0
5.71 5.20 34.2 33.9
7.60 7.33 33.2 33.2
7.26 6.81 34.0 33.9
6.14 5.86 33.2 33.2
5.25 4.96 34.8 34.7
7.98 7.70 34.2 34.0
7.30 6.94 36.0 35.9
Table 2 Model estimates of predictors of HIV-positive status according to GEE analysis
Independent variables Complete dataset Imputed dataset
Estimate SE P value Estimate SE P value
Intercept −0.593 0.050 <0.001 −0.631 0.048 <0.001
Calendar year −0.277 0.038 <0.001 −0.254 0.036 <0.001
Year of birth −0.039 0.009 <0.001 −0.043 0.009 <0.001
Year of birtha −0.054 0.012 <0.001 −0.042 0.010 <0.001
Year of birthb 0.019 0.005 <0.001 0.013 0.005 0.012
Age 0.043 0.009 <0.001 0.035 0.008 <0.001
Agec −0.048 0.006 <0.001 −0.043 0.006 <0.001
Aged 0.012 0.002 <0.001 0.011 0.002 <0.001
Female, non-Swiss, non-injector −1.760 0.492 <0.001 −1.435 0.543 0.011
Female, non-Swiss, ever injector 0.497 0.158 0.002 0.457 0.150 0.002
Female, Swiss, non-injector −1.344 0.197 <0.001 −1.372 0.201 <0.001
Female, Swiss, ever injector 0.186 0.069 0.007 0.167 0.065 0.011
Male, non-Swiss, non-injector −1.520 0.299 <0.001 −1.422 0.261 <0.001
Male, non-Swiss, ever injector −0.074 0.109 0.496 −0.087 0.107 0.417
Male, Swiss, non-injector −1.547 0.149 <0.001 −1.567 0.143 <0.001
The time variables were rescaled to fit the GEE model as follows: calendar year = logarithm of year − 1990, year of birth = year − 1960, age = age − 30. aYear of
birth = Year of birth × Year of birth / 10. bYear of birth = Year of birth × Year of birth × Year of birth / 100. cAge = Age × Age / 10, dAge = Age × Age × Age / 100. The
group ‘Male, Swiss, ever injector’ was reference category and is therefore omitted from the independent variable list. SE, standard error.
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plotted by calendar year, year of birth, and age, respect-
ively (Figure 1). As can be seen from the graphs, patients
born between 1951 and 1964 had the highest HIV preva-
lence (about 25%), and HIV prevalence increased until the
age of 35 years and then stabilized. However, all groups of
non-injectors had a four to five times lower RR of HIV
prevalence as the reference group of Swiss males who ever
injected (Table 3). A significantly higher risk ratio of HIV
prevalence appeared among ever-injecting females in the
complete dataset, as well as in the imputed dataset (SwissFigure 1 HIV prevalence using all data from the complete and the im
treatment. Plotted by calendar year, year of birth, or age, respectively.RR 1.18, CI 95% 1.04–1.34; non-Swiss RR 1.58, CI 95%
1.18–2.12). Finally, the declining trend in HIV prevalence
during the calendar year was equal for all subgroups, re-
gardless of gender, nationality, or lifetime injecting status
(Figure 2).
Discussion
In analyzing this case register, we aimed to identify
ethnic- and gender-specific differences in the prevalence
of HIV among heroin users receiving opioid mainte-
nance treatment in the canton of Zurich, Switzerland.puted long dataset. One record per patient for each year being in
Table 3 Risk ratio (RR) of predictors of HIV-positive status according to GEE analysis
Independent variables Complete dataset Imputed dataset
RR CI 95%− CI 95%+ RR CI 95%− CI 95%+
Calendar year 0.76 0.70 0.82 0.78 0.72 0.83
Year of birth 0.96 0.94 0.98 0.96 0.94 0.97
Year of birtha 0.95 0.93 0.97 0.96 0.94 0.98
Year of birthb 1.02 1.01 1.03 1.01 1.00 1.02
Age 1.04 1.03 1.06 1.04 1.02 1.05
Agec 0.95 0.94 0.96 0.96 0.95 0.97
Aged 1.01 1.01 1.02 1.01 1.01 1.02
Female, non-Swiss, non-injector 0.17 0.07 0.45 0.24 0.08 0.69
Female, non-Swiss, ever injector 1.64 1.21 2.24 1.58 1.18 2.12
Female, Swiss, non-injector 0.26 0.18 0.38 0.25 0.17 0.38
Female, Swiss, ever injector 1.20 1.05 1.38 1.18 1.04 1.34
Male, non-Swiss, non-injector 0.22 0.12 0.39 0.24 0.14 0.40
Male, non-Swiss, ever injector 0.93 0.75 1.15 0.92 0.74 1.13
Male, Swiss, non-injector 0.21 0.16 0.28 0.21 0.16 0.28
The time variables were rescaled to fit the GEE model as follows: calendar year = logarithm of year − 1990, year of birth = year − 1960, age = age − 30. aYear of
birth = Year of birth × Year of birth / 10. bYear of birth = Year of birth × Year of birth × Year of birth / 100. cAge = Age × Age / 10, dAge = Age × Age × Age / 100. The
group ‘Male, Swiss, ever injector’ was reference category and is therefore omitted from the independent variable list.
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lence of HIV among opioid-maintained patients, regard-
less of gender and nationality, during the first years after
initiation of the register in 1991. The following years
were associated with a more stable prevalence of HIV in
this subgroup.
These findings are in line with previously available
data from the Swiss Federal Office of Public Health and
the SWISS HIV Cohort Study [19,24,26] and under-
line the effectiveness of measures that have been taken
since HIV/AIDS became a major public health concern
in the context of open drug scenes that developed in
Switzerland’s largest cities in the early 1980s. Between
1985 and 1995, HIV/AIDS incidence and prevalence ratesFigure 2 HIV prevalence using all data from the imputed long datase
calendar year, separate for gender, nationality and method of drug use.were the highest in Europe [56,57]. Virus transmission by
contaminated syringes and needles among an estimated
3,000 IDUs contributed significantly to this crisis [57].
Although methadone prescription and maintenance treat-
ment had been introduced almost a decade earlier and
all physicians could prescribe methadone until 1975,
controlled-substance legislation was inconsistent and os-
cillated between liberal and restrictive approaches [21]. In
the face of this heroin and HIV/AIDS epidemic, a harm-
reduction-friendly policy was adopted in 1991 at the
federal level [21,57], which formally permitted the imple-
mentation of low-threshold methadone programs, needle-
and syringe-exchange services, supervised consumption
rooms, and heroin-assisted treatments [58].t. One record per patient for each year being in treatment. Plotted by
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practice in 1991, administrative barriers in Zurich (and
other Swiss cities) were greatly reduced [59], since it was
recognized that high-entry barriers keep opiate-dependent
users from seeking admission to OMT. Since then, this
finding has been widely and repeatedly replicated [60-63].
Furthermore, studies from Canada show that limited
provision of addiction treatment may result not just in a
missed opportunity to reduce HIV transmission behavior
among IDUs [64] but could lead to increased HIV-related
expenditures for the general public [65].
Other than suffering from an opiate dependence, there
were no further prerequisites to enter treatment. Fur-
thermore, medical care and prescription of opioids such
as methadone and buprenorphine were covered by man-
datory health insurance, and sufficient OMT providers
were involved to avoid waiting lists. The introduction of
an on-call service, staffed 24/7, allowed the admission of
opiate-dependent patients into an OMT and the dis-
pensation of a first dosage of methadone without delay.
Both cantonal and private treatment institutions offered
multidisciplinary approaches and were usually staffed by
psychiatrists and internal medicine specialists with nur-
ses, as well as social workers, to provide widespread sup-
port [21,57]. Special attention was given to pregnant
women suffering from opioid dependence to ensure
easy access to OMT during pregnancy and after child-
birth [66].
It was estimated that OMT attracts around 64% of
Zurich’s opioid-dependent patients [51]. Furthermore,
every second individual with a problematic use of opi-
oids will, regardless of gender, seek admission into a pro-
gram within 2–3 years after developing dependency [51].
Despite this low-threshold approach, our findings sug-
gest that gender and migration background influence the
risk of being HIV positive. Different access to treatment
and different exposure risk characteristics for certain sub-
groups may offer possible explanations for these findings
[67-69]. A recent review identified pregnancy, lack of ser-
vices for pregnant women, fear of losing custody for a
newborn, or fear of prosecution, coupled with lack of
childcare outside of treatment, to be gender-specific
barriers keeping women from entering treatment for
substance use disorders in general [70-72]. Addition-
ally, women may not just lack social support, but ex-
perience greater social stigma and discrimination than
their male counterparts, when entering such treatment
[70,73,74]. Women have also been reported to articulate
more negative expectations about treatment than males
[70,75]. A number of studies documented systematic bar-
riers—irrespective of gender—related to the policies and
procedures of OMT [76]. They include multiple require-
ments for treatment initiation or modification (including
waiting lists), rules regarding abstinence, requirementsof established health insurance, hidden or collateral fees,
requirements to prove identification, limited take-home
dose availability, and a lack of information regarding treat-
ment options [77,78]. One aspect may be that drug-
related services in Switzerland do not tend to be culture-
specific, so as not to specifically arrange services for
certain migrant subgroups, which may have the effect
of increasing the likelihood of cultural misperception
and overlook social variables. Previous studies elsewhere
showed that migrants without legal documentation might
avoid seeking medical advice or entering treatment
services because of fear of expulsion from the country
[27,79]. Furthermore, some authors reported a more
serious progression of opioid dependence in an immi-
grant population (leading to the acquisition of mul-
tiple infections) and interpreted this finding as part of
a multifaceted acculturation problem [80].
In addition, the higher risk for native women and
for women with a migration background warrants fur-
ther research and should identify what factors deter wo-
men from using available HIV-prevention measures,
as well as whether these measures need to be better
adapted to high-risk groups. This becomes even more
apparent in light of a recent study among a Canadian
cohort of HIV-positive individuals in IDUs, which iden-
tified female gender as an additional barrier to access
and adherence to antiretroviral therapy once women
had been infected—a finding that was independent of
drug use and other socio-behavioral and clinical cha-
racteristics [81].
We acknowledge the limitations of our study. First,
Switzerland’s immigration policy is strictly controlled,
especially in relation to individuals from non-EU mem-
ber states and relies on a system of quotas and permits
(short-term permit (L), initial residence permit (B), per-
manent residence permit (C), and cross border com-
muter permits (G)) and may prevent naturalization for
two or more generations [82]. Our calculations might
therefore have falsely categorized individuals as non-
native who were actually born and raised in Switzerland
(i.e., granting nationality on the basis of jus sanguinis
(‘right of blood’), as compared to those granting it on
the grounds of jus soli (‘right of soil’), such as the USA.
Second, because of our small sample size, we cannot
provide a finer breakdown for analysis than Swiss and
non-Swiss; therefore, the latter is an extremely heteroge-
neous group that includes individuals from the majority
of European and Eastern European countries, as well as
a few subjects of Arabic or African ethnic background.
Nevertheless, our database of OMT is one of the oldest
in existence and is the largest of its kind in Europe, so
our findings might still be useful when comparing HIV
prevalence rates internationally, especially in relation to
gender and immigration background.
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These findings provide insights into ethnic- and gender-
specific differences in the prevalence of HIV among her-
oin users receiving opioid maintenance treatment in the
canton of Zurich, Switzerland. In this sample, overall pre-
valence rates of HIV decreased significantly since 1991,
which can be associated with the introduction of wide-
spread harm-reduction measures. In particular, the higher
risk for women who inject drugs, and especially for wo-
men with a migrant background, warrants additional
research and needs to address what factors deter this
subgroup from using available HIV-prevention measures.
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